Repeated loco-regional therapies for hepatocellular carcinoma is associated with inferior outcome after living donor liver transplantation in cirrhotic patients

被引:3
作者
Tsou, Yi-Fan [1 ]
Lin, Niang-Cheng [1 ]
Hsia, Cheng-Yuan [1 ,2 ]
Loong, Che-Chuan [1 ,2 ]
Tsai, Hsin-Lin [1 ,3 ]
Chen, Cheng-Yen [1 ]
Lei, Hao-Jan [1 ,2 ]
Chou, Shu-Cheng [1 ,2 ]
Chung, Meng-Hsuan [1 ]
Kuo, Fang-Cheng [1 ]
Liu, Chin-Su [1 ,3 ]
机构
[1] Taipei Vet Gen Hosp, Dept Surg, Div Transplantat Surg, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan
[3] Taipei Vet Gen Hosp, Dept Surg, Div Pediat Surg, Taipei, Taiwan
关键词
Hepatocellular carcinoma; Liver transplantation; Living donor liver transplantation; Loco-regional therapy; Outcomes; CHEMOEMBOLIZATION; IMPACT;
D O I
10.1097/JCMA.0000000000000670
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Liver transplantation is the definitive treatment for defined stage hepatocellular carcinoma (HCC) in cirrhotic patients. Loco-regional therapy (LRT) may be considered before transplantation to prevent the disease progression and the patient from dropping out of the waiting list. This study aims to evaluate the impact of repeated pretransplant LRTs on the long-term outcomes in HCC liver transplant recipients. Methods: Between 2004 and 2019, living donor liver transplantation (LDLT) recipients with viable HCC on the explant livers were enrolled. Uni- and multivariate analysis was performed with the Cox regression model to stratify the risk factors associated with HCC recurrence and patent survival after LDLT. Results: A total of 124 patients were enrolled, in which 65.3% (n = 81) were Barcelona Clinic Liver Cancer classification stage B or D and 89% (n = 110) had advanced fibrosis or cirrhosis on the explanted livers. After a median follow-up of 41 months (IQR: 24-86.5), there were 18 cases (13.7%) of HCC recurrence. Univariate analysis showed that the model of end-stage liver disease and Child-Turcotte-Pugh score, pretransplant alpha-fetoprotein value (>500 ng/ml), repeated pretransplant LRTs (N > 4), increased tumor numbers and maximal size, presence of microvascular invasion, and the histological grading of the tumors are risk factors of inferior outcomes. In multivariate analysis, only repeated pretransplant LRTs (N > 4) had a significant impact on both the overall- and recurrence-free survival. The impact of pretransplant LRT was consistently significant among subgroups based on their LRT episodes (N = 0, 1-4, >4 respectively). Conclusion: Repeated LRT for HCC can be associated with the risk of tumor recurrence and inferior patient survival after LDLT in cirrhotic patients. Early referral of those eligible for transplantation may improve the treatment outcomes in these patients.
引用
收藏
页码:317 / 323
页数:7
相关论文
共 50 条
  • [21] Inferior Outcomes Associated with the Coexistence of Hepatocellular Carcinoma Recurrence and Hepatic Virus Reinfection After Living Donor Liver Transplantation
    Chan, Kun-Ming
    Wu, Tsung-Han
    Cheng, Chih-Hsien
    Lee, Chen-Fang
    Wu, Ting-Jung
    Chou, Hong-Shiue
    Lee, Wei-Chen
    JOURNAL OF GASTROINTESTINAL SURGERY, 2020, 24 (02) : 353 - 360
  • [22] Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation
    Na, Gun Hyung
    Hong, Tae Ho
    You, Young Kyoung
    Kim, Dong Goo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (25) : 5790 - 5799
  • [24] Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma
    Antwi, Samuel O.
    Habboush, Yacob Y.
    Chase, Lori A.
    Lee, David D.
    Patel, Tushar
    ANNALS OF HEPATOLOGY, 2018, 17 (06) : 969 - 979
  • [25] Early recurrence of hepatocellular carcinoma after living donor liver transplantation
    Ohkubo, T
    Sugawara, Y
    Imamura, H
    Kaneko, J
    Matsui, Y
    Makuuchi, M
    HEPATO-GASTROENTEROLOGY, 2004, 51 (55) : 237 - 238
  • [26] Renal metastasis of hepatocellular carcinoma after living donor liver transplantation
    Nakamura, Yo
    Kamei, Jun
    Tanaka, Ryo
    Yasunaga, Yoichi
    Akamatsu, Nobuhisa
    Taguchi, Satoru
    Kakutani, Shigenori
    Yamada, Yuta
    Niimi, Aya
    Yamada, Daisuke
    Kume, Haruki
    IJU CASE REPORTS, 2025, 8 (02) : 133 - 137
  • [27] Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective
    Yoon, Young-In
    Lee, Sung-Gyu
    DIGESTIVE DISEASES AND SCIENCES, 2019, 64 (04) : 993 - 1000
  • [28] Impact of incidentally found hepatocellular carcinoma on the outcome of living donor liver transplantation
    Kishi, Yoji
    Sugawara, Yasuhiko
    Tamura, Sumihito
    Kaneko, Junichi
    Kokudo, Norihiro
    Makuuchi, Masatoshi
    TRANSPLANT INTERNATIONAL, 2006, 19 (09) : 720 - 725
  • [29] A case report of de novo hepatocellular carcinoma after living donor liver transplantation
    Songfeng Yu
    Hua Guo
    Li Zhuang
    Jun Yu
    Sheng Yan
    Min Zhang
    Weilin Wang
    Shusen Zheng
    World Journal of Surgical Oncology, 11
  • [30] Survival Analysis after Living Donor Liver Transplantation for Hepatocellular Carcinoma: A Single Center Cohort Study
    Na, Byung-Gon
    Kim, Seong-Hoon
    Park, Sang-Jae
    BIOLOGY-BASEL, 2021, 10 (05):